Efficacy of biologic agents in improving the Health Assessme(9)

Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis a meta-analysis with indirect comparisons

logic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54: 2807-16.38. WESTHOVENS R, COLE JC, LI T et al.: Im-proved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicenter randomized clinical trial. Rheumatology 2006; 45: 1238-46.

39. TAK PP, RIGBY WF, RUBBERT-ROTH A et al.:

Inhibition of joint damage and improved 41. EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSKA A et al.: The efficacy and safety of rituximab in patients with active rheuma-toid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.

42. JONES G, SEBBA A, GU J et al.: Comparison of

tocilizumab monotherapy versus methotrex-ate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.

tocilizumab in combination with traditional disease-modifying antirheumatic drug thera-py study. Arthritis Rheum 2008; 58: 2968-80.45. EMERY P, KEYSTONE E, TONY HP et al.: IL-6

receptor inhibition with tocilizumab improves treatment outcomes in patients with rheuma-toid arthritis refractory to anti-tumour necro-sis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.

46. GABAY C, EMERY P, Van VOLLENHOVEN R et

al.: Tocilizumab monotherapy versus adali-clinical outcomes with rituximab plus metho-trexate in early active rheumatoid arthritis: the IMAGE trial. 40. 39-46.

Ann Rheum Dis 2011; 70: COHEN SB, EMERY P, GREENWALD MWRituximab for rheumatoid arthritis refractory et al.:

to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary weeks. Arthritis Rheumefficacy and safety 2006; 54: 2793-806.

at twenty-four 43. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH Aet al.tion with tocilizumab in patients with rheu-: Effect of interleukin-6 receptor inhibi-

matoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. 44. LancetGENOVESE MC, M 2008; 371: 987-97.

et al.CKAY JD, NASONOV EL

tocilizumab reduces disease activity in rheu-: Interleukin-6 receptor inhibition with matoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the

341

mumab monotherapy for treatment of rheu-matoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet47. 2013; 381: 1541-50.

SCHIFF M, KEISERMAN M, CODDING CEfficacy and safety of abatacept or infliximab et al.:

vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to metho-trexate. Ann Rheum Dis 2008; 67:1096-103.

百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读，免费范文网，提供经典小说综合文库Efficacy of biologic agents in improving the Health Assessme(9)在线全文阅读。